Article Listing - Research briefs on Merck & Co’s boceprevir and Bayer’s Xarelto; legal updates from AstraZeneca and Daiichi Sankyo/Actavis

GENERIC VERSION OF MAXZIDE-25 APPROVED

25 May 1992

- Geneva Pharmaceutical has received the first generic approval of a version of Mylan's Maxzide-25 (triamterene and hydrochloro-thiazide) from the...

THALASSEMIA DRUG STUDY

25 May 1992

- Researchers from the Hospital for Sick Children, Toronto, are to publish a favourable study for the thalassemia drug, L-1....

MYLAN'S GENERIC METHOTREXATE

25 May 1992

- Mylan Laboratories has received an approval from the US Food and Drug Administration to manufacture and market generic tablets...

YUGOSLAV COS "INTEGRATE"

25 May 1992

Farmakos, the only factory producing medical supplies in the Serbian province of Kosovo, has been adversely affected by ethnic Albanians...

MARS STUDY REVEALS NEW REGRESSION DATA

25 May 1992

New data has been presented by Merck Sharp & Dohme to support the growing body of research showing that atherosclerosis...

Synthelabo's Product Portfolio

25 May 1992

*t Product Class...

WHA: CONSUMERISTS & ETHICAL CRITERIA

25 May 1992

Ethical Criteria for Medicinal Drug Promotion attracted heated debate and lobbying during this year's World Health Assembly, the 45th, (Marketletter...

BIOTEST ON EXPANSION COURSE

25 May 1992

The German manufacturer of hospital products for the treatment of blood diseases and blood analysis, Biotest AG, says that it...

"GLITTERING YEAR" FOR ANZAG

25 May 1992

Andreae-Noris Zahn (Anzag), the German drug wholesaling group, has reported a "glittering" 1991, but expects 1992 sales to be below...

CIBA-GEIGY CITES "SINISTER TENDENCY"

25 May 1992

Alex Krauer, chairman of Swiss pharmaceutical and chemical concern, Ciba-Geigy, referred in his address at the company's annual general meeting...

Showing 94031-94040 of 95586 articles